The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir

This study looks at how well a long-acting injectable HIV prevention drug (cabotegravir, given as a shot every 2 months) called CAB-LA is used in real-world clinical settings for young men (18–30) who are at risk of HIV through anal sex. This type of drug is called PrEP (pre-exposure prophylaxis) — it prevents HIV infection before it occurs. **You may be eligible if...** - You are a cisgender man, non-binary person assigned male at birth, or transgender woman or man, aged 18–30 - You have had anal sex with a person assigned male at birth in the last 6 months - You are seeking PrEP at a study clinic - You are HIV-negative and have not previously taken CAB-LA or standard PrEP pills - You are willing to attend follow-up visits and complete study requirements **You may NOT be eligible if...** - You already have HIV - You are 31 years or older, or younger than 18 - You have previously used CAB-LA or TDF/FTC PrEP - You have significant liver disease - You are not seeking PrEP (not at risk or not interested in prevention) Talk to your doctor to see if this trial is right for you.